Testing a new PNH pill for people who haven't had complement therapy
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a new oral medication called MY008211A for people with PNH who have not yet tried complement inhibitors. It aims to improve anemia and reduce the need for blood transfusions by targeting the part of the immune system that destroys red blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have a BMI of 18 or higher.
- Your PNH must affect at least 10% of your red blood cells (confirmed by a special blood test).
- You must have low hemoglobin (less than 100 g/L) and high LDH (a marker of red blood cell breakdown) at screening.
- You must receive a meningitis vaccine before starting the study. Vaccines for certain other infections are also recommended if you haven't had them.
- You cannot have had a stem cell or bone marrow transplant, or your spleen removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This study tests a new oral medication called NTQ5082 for people with PNH who have not been treated with a complement inhibitor before. It aims to see if the drug can reduce the breakdown of red blood cells and improve anemia.
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
This trial is testing a new pill (FXS6837) compared to the standard IV medicine eculizumab for people with PNH. The study lasts 24 weeks and aims to see if the new pill works better or as well and has fewer side effects.
This study checks the long-term safety of the drug MY008211A for people with paroxysmal nocturnal hemoglobinuria (PNH). It is only for those who already took the drug in an earlier study and had benefit, and who have had specific vaccines.
This clinical trial tests an investigational drug called EA5 for people with PNH, a rare blood disease where red blood cells break down too quickly. It is for adults who either have never taken a complement inhibitor or stopped taking one recently, and who still have signs or symptoms of PNH.
Hear when a new Paroxysmal Nocturnal Haemoglobinuria (PNH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.